Status: Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Participants needed: 125
Trial details
Phase: Phase 3Age: 18-85Biological sex: AllType: InterventionalSponsor: Alnylam PharmaceuticalsUpdated: Jun 12, 2026Locations: 29
Eligibility criteria
Has documented diagnosis of hATTR-PN [+3]
Has had a liver transplant or is likely, in the opinion of the Investigator, to... [+6]